Physician profile
Paul E Moore
NPI 1326002023
$4,697.38
in general payments reported to CMS, 2019-2025
43 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $240 · 2021: $425 · 2022: $323 · 2023: $816 · 2024: $820 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.46 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.96 | 2019-2025 | |
| Novo Nordisk INC | $477.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $462.86 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $359.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $327.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $230.60 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $220.85 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $204.01 | 2019-2021 | |
| Atricure, INC. | $187.76 | 2024-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.13 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $157.19 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.29 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $94.47 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $88.13 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $83.89 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.